Clinical trials: Cholangiocarcinoma Cancer
Cholangiocarcinoma, Intrahepatic
Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma
In this phase 2 study, we aim to evaluate the effects and safety of combined therapy using nab-paclitaxel and gemcitabine chemotherapy for patients after radical resection of Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04077983
- Testing
- combined therapy using nab-paclitaxel and gemcitabine chemotherapy
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pain
- Trial name
- NCT00073905
- Testing
- capecitabine plus gemcitabine
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Swiss Cancer Institute
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Pancreatic Cancer, Lymphadenopathy
Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle
The primary objective of this proposed prospective randomized, multi-center study is to evaluate the capability of the new 22G SharkCore™ needle to obtain tissue specimens and to compare its performance against the standard 22G…
- Conditions
- Pancreatic Cancer, Lymphadenopathy, Cholangiocarcinoma
- Trial name
- NCT02872831
- Testing
- 22G SharkCore™ needle, 22G BNX EUS-FNA Needle
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Biliary Obstruction, Pancreas Neoplasm
EUS-guided Choledochoduodenostomy for Primary Drainage of Malignant Distal Biliary Obstruction
A prospective single-centre pilot study investigating the feasibility and safety of EUS-guided choledochostomy as primary drainage strategy in patients with distal malignant biliary obstruction using a FCSEMS through LAMS to…
- Conditions
- Biliary Obstruction, Pancreas Neoplasm, Distal Cholangiocarcinoma
- Trial name
- SCORPION-II-p (NCT05595122)
- Testing
- EUS-CDS
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Ovarian Neoplasms, Peritoneal Neoplasms
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine.
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT05194072
- Testing
- Felmetatug Vedotin, Pembrolizumab
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 250 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
This phase II trial studies how well trifluridine/tipiracil and irinotecan work in treating patients with biliary tract cancer that has spread to other places in the body (advanced) and has not responded to treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma, Refractory Gallbladder Carcinoma
- Trial name
- NCT04072445
- Testing
- Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Cholangiocarcinoma
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
- Trial name
- NCT06718257
- Testing
- Gemcitabine combined with cisplatin or oxaliplatin, Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
A IIT Study of 177Lu-DOTA-SNA040
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced…
- Conditions
- Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction), Advanced Solid Tumors (Such as Pancreatic Cancer), Advanced Solid Tumors (Such as Cholangiocarcinoma)
- Trial name
- NCT07595237
- Testing
- 177Lu-DOTA-SNA040
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
Liver Cancer, Bile Duct Cancer
Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis
Only a small proportion of patients with biliary obstruction caused by hepatopancreatobiliary malignancies are suitable for surgical resection.
- Conditions
- Liver Cancer, Bile Duct Cancer, Pancreatic Cancer
- Trial name
- NCT02841800
- Testing
- 'Intra-luminal radiofrequency ablation (Habib EndoHPB)
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Anal Cancer, Colorectal Cancer
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
RATIONALE: Gathering information about patients' quality of life during radiation therapy for cancer may help doctors plan the best treatment.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00836992
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Mayo Clinic
Cholangiocarcinoma
RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma
Extrahepatic cholangiocarcinoma is a malignant tumor that is highly malignant and difficult to diagnose and treat early. Endobiliary radiofrequency ablation (RFA) has been reported to be a beneficial treatment option for…
- Trial name
- NCT05028439
- Testing
- radiofrequency ablation, Chemotherapy drug
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First People's Hospital of Hangzhou
Intrahepatic Cholangiocarcinoma, Machine Learning
A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma
The object of this study is to develop a model for prediction of lymph node metastasis among intrahepatic cholangiocarcinoma (ICC) patients.
- Trial name
- NCT06290739
- Testing
- lymph nodes dissection
- Where
- China
- Volunteers
- 483 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Cholangiocarcinoma
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
To find out if adding pembrolizumab to standard of care chemotherapy drugs (cisplatin and gemcitabine) will improve long-term response of intrahepatic cholangiocarcinoma after surgery, compared to treatment with surgery and…
- Trial name
- NCT05967182
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer, Hepatocellular Carcinoma
A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy
The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer. One treatment plan will be created using routine procedures and scans normally performed for radiation treatment…
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03338062
- Testing
- Hepatobiliary Iminodiacetic Acid (HIDA) scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Cholangiocarcinoma
Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples
Cholangiocarcinoma is a malignancy that is most-often diagnosed with ERCP-directed cytology brushings of the biliary tree, but the yield on this cytology has been previously shown to only be 5%-40%.
- Trial name
- NCT06651346
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Virginia
Cholangiocarcinoma, Colorectal Cancer
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare…
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
- Trial name
- NCT06910670
- Testing
- Standard developed materials, Genetics Advisor Decision Aid
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Washington University School of Medicine
Neoplasms, Non-Neoplastic
AI Guidance for Biopsy in Suspected Cholangiocarcinoma
Digital single-operator cholangioscopy (DSOC) has emerged as a medical advance with an important role in the evaluation of indeterminate biliary lesions.
- Conditions
- Neoplasms, Non-Neoplastic, Bile Duct Neoplasms, Bile Duct Lesions
- Trial name
- NCT05374122
- Testing
- DSOC with AI biopsy guidance, DSOC biopsy without AI guidance
- Where
- Ecuador
- Volunteers
- 48 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma.
- Trial name
- NCT03773302
- Testing
- BGJ398, Gemcitabine, Cisplatin
- Where
- 116 sites in United States, Australia and 13 more
- Volunteers
- 48 people
- Sponsor
- QED Therapeutics, a BridgeBio company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.